Clinical Trial Update: Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating anlotinib in recurrent or metastatic nasopharyngeal carcinoma after failure of at least second-line therapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Carcinoma | Phase 2 | Status: COMPLETED